Sikic Lab clinical research
Current adult clinical protocols of modulation of drug resistance
and antisense gene therapy at Stanford University Medical Center.
For a complete listing of all cancer protocols and patient contact information,
please consult the General
Clinical Research Center web page.
For information regarding active clinical trials in the United States,
please contact the National Cancer Institute
at 1-800-4-CANCER (422-6237).
| Protocol | Investigator | Protocol Title |
|---|---|---|
| 463 | Greenberg | Phase II Trial of Mitoxantrone, Etoposide, Cytarabine and PSC 833 (PSC-MEC) Therapy in Patients with Relapsed and Acute Myeloid Leukemia |
| 474 | Sikic | Phase II Trial of Paclitaxel and PSC 833 in Metastatic Colorectal Carcinoma |
| 509 | Sikic | Phase II Trial of ISIS 3521 (CGP 64128A) An Antisense Inhibitor of Protein Kinase C in Patients with Ovarian Cancer |
| 523 | Sikic | Phase I Trial of ISIS 3521 Administered by 24 Hour Weekly Infusion in Patients with Advanced Cancer |
| 551 | Sikic | Phase I Trial of Doxil, Paclitaxel and PSC 833 |
| 560 | Sikic | Phase I Dose Escalating Study of LY335979 in Combination with Mitoxantrone in Patients with Hormone-Refractory Prostate Cancer |
| 567 | Sikic | Phase I Trial of Oral Paclitaxel and Valspodar (PSC833) |
| 617 | Sikic | Phase I Study of Weekly BMS-188797 Alone and in Combination with Carboplatin in Patients with Advanced Malignancies |
| 663 | Sikic | A Prospective, Randomized, Open Label Phase III Trial of Chemotherapy with Carboplatin and Paclitaxel vs Carboplatin and Paclitaxel in Combination with ISIS 3521 |
| 670 | Sikic | A Phase I Study of ZD1839 (Iressa) in Combination with Oxaliplatin, 5FU, and Leukovorin in Advanced Solid Malignancies |
Related Publications
- Fisher GA, Lum BL, Hausdorff J and SikicBI. Pharmacological considerations
in the modulation of multidrug resistance. European Journal of Cancer
32A: 1082~1088, 1996. [PDF
Reprint]
- Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr
A, and Sikic BI. Phase I study of an antisense oligonucleotide to protein
kinaseC-alpha (ISIS 3521/CGP 64128A1) in patients with cancer. Clinical
Cancer Research 5: 3357–3363, 1999. [PDF
Reprint]
- Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan
K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, and Greenberg
PL. Treatment of refractory and relapsed acute myelogenous leukemia
with combination chemotherapy plus the multidrug resistance modulator
PSC 833 (valspodar). Blood 93: 787-795, 1999. [PDF
Reprint]
- Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ,
Chang M, Sikic BI, and Arceci RJ. Mitoxantrone, etoposide, and cyclosporine
therapy in pediatric patients with recurrent or refractory acute myeloid
leukemia. Journal of Clinical Oncology 18: 1867-1875, 2000. [PDF
Reprint]
- Lum BL, Kaubisch S, Fisher GA, Brown BW, and Sikic BI. Effect of high-dose
cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein
(MDR1 gene) mediated drug resistance. Cancer Chemotherapy
and Pharmacology 305-11, 2000. [PDF
Reprint]
- Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, and
Sikic BI. A phase I trial of doxorubicin, paclitaxel, and valspodar
(PSC 833), a modulator of multidrug resistance. Clinical Cancer Research
7(5):1221-9, 2001. [PDF Reprint]
- Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN,
Bomgaars L, Lauer SJ, Sikic BI, and Dahl GV. Pharmacokinetic interactions
of cyclosporine with etoposide and mitoxantrone in children with acute
myeloid leukemia. Leukemia 16: 920-7, 2002. [PDF
Reprint]
- Chin DL, Lum BL, and Sikic BI. Rapid determination of PEGylated liposomal
doxorubicin and its major metabolite in human plasma by ultraviolet-visible
high-performance liquid chromatography. Journal of Chromatography
779: 259-69, 2002. [PDF
Reprint]
- Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri
A, and Sikic BI. Phase I and pharmacokinetic study of BMS-188797, a
new taxanee analog, administered on a weekly schedule in patients with
advanced malignancies. Clinical Cancer Research 9: 5187-94,
2003. [PDF Reprint]
- Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI,
Shapiro R, and Stockdale FE. Phase I trial of uracil-ftorafur, leucovorin,
and etoposide: an active all-oral regimen for metastatic breast cancer.
Clinical Cancer Research 9: 5187-94, 2003. [PDF
Reprint]
- Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ,
Halsey J, Holmlund JT, Dorr A, and Sikic BI. A phase II trial of aprinocarsen,
an antisense oligonucleotide inhibitor of protein kinase C alpha, administered
as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer
100: 321-6, 2004. [PDF
Reprint]
- Greenberg PL, Lee SJ, Advani R, Tallman
MS, Sikic BI, Letendre L, Dugan K, Lum BL, Chin DL, Dewald G, Paietta
E, Bennett JM, and Rowe JM. Mitoxantrone, etoposide, and cytarabine
with or without valspodar in patients with relapsed or refractory
acute myeloid leukemia and high-risk myelodysplastic syndrome: a
phase III trial (E2995). J Clin Oncol. 22: 1078-86, 2004.
[PDF Reprint]
- Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, and Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104: 2646-54, 2004. [PDF Reprint]
